# Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.

> **NCT00191711** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 43 (—)

## Conditions studied

- Superficial Bladder Cancer

## Interventions

- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00191711
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 43 (—)
- **Last updated:** 2007-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191711, "Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00191711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*